Lördag 2 Augusti | 09:34:38 Europe / Stockholm

Svenska | English

Evaxion Biotech A/S

Filter

År

Typ

Språk

Rensa

2025-07-25 15:00:04 Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

2025-07-11 14:00:36 Evaxion finalizes agreement with EIB to convert debt into equity 2,66 USD | +3,10%

2025-07-01 14:30:29 Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio 2,48 USD | +1,22%

2025-06-25 14:00:38 Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus 2,59 USD | +5,71%

2025-06-03 15:15:31 Evaxion receives grant funding to design new polio vaccine 2,74 USD | +0,74%

2025-05-27 13:30:48 Evaxion announces business update and first quarter 2025 financial results 2,36 USD | +25,53%

2025-05-23 14:00:51 Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 1,88 USD | +0,53%

2025-05-22 14:00:12 Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 1,87 USD | +25,50%

2025-04-28 14:00:41 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting 1,65 USD | 0,00%

2025-04-10 14:00:38 Evaxion to present at World Vaccine Congress 1,35 USD | +1,50%

2025-04-01 13:30:35 Evaxion announces business update and full year 2024 financial results 1,66 USD | -10,27%

2025-03-27 13:00:21 Evaxion to announce business update and full year 2024 financial results on April 1, 2025 1,76 USD | -0,56%

2025-03-25 21:30:39 Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting 1,75 USD | -7,89%

2025-03-04 14:00:00 Evaxion to present at numerous upcoming conferences 1,87 USD | -1,06%

2025-02-25 14:00:00 Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package 2,17 USD | -11,07%

2025-02-14 14:00:00 Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination 2,49 USD | -4,60%

2025-01-31 22:05:00 Evaxion announces closing of $10.8 million public offering 2,46 USD | -0,61%

2025-01-30 14:00:00 Evaxion announces pricing of $10.8 million public offering 2,47 USD | -27,14%

2025-01-28 14:15:00 Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement 4,37 USD | -27,17%

2025-01-15 14:00:00 Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 3,29 USD | -12,94%

2025-01-14 22:05:00 Evaxion announces completion of ADS ratio change 3,78 USD | +344,60%

2025-01-10 14:00:00 Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change 0,90 USD | +1,12%

2024-12-30 14:00:00 Evaxion announces plan to implement ADS ratio change 0,96 USD | -9,63%

2024-12-17 14:00:00 Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity 0,96 USD | -8,92%

2024-12-12 14:00:00 Evaxion establishes new AI-derived precision cancer vaccine concept 1,19 USD | -8,46%

2024-12-09 14:00:00 Evaxion announces 2025 milestones reflecting continued strong strategy execution 1,32 USD | -1,49%

2024-12-02 14:00:00 Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress 1,54 USD | -7,23%

2024-11-13 14:00:00 Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing 1,76 USD | -26,05%

2024-11-12 14:00:00 Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 2,38 USD | -1,65%

2024-10-31 13:00:00 Evaxion announces business update and third quarter 2024 financial results 2,67 USD | -3,26%

2024-10-28 13:00:00 Evaxion to announce business update and third quarter 2024 financial results on October 31 2,84 USD | +2,90%

2024-10-09 14:00:00 Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials 2,68 USD | -5,63%

2024-10-03 14:00:00 Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform 3,06 USD | +2,68%

2024-09-26 13:30:00 Evaxion significantly expands vaccine development collaboration with MSD 3,06 USD | +8,13%

2024-09-19 14:00:00 Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction 3,15 USD | +0,96%

2024-09-16 13:00:00 Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 3,25 USD | +8,33%

2024-09-09 14:00:00 Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01 3,25 USD | -5,80%

2024-09-09 13:00:00 Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 3,25 USD | -5,80%

2024-08-14 13:00:00 Evaxion Announces Business Update and Second Quarter 2024 Financial Results 2,75 USD | +1,72%

2024-08-12 13:27:00 Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14 2,49 USD | -2,51%

2024-08-08 14:00:00 Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September 2,30 USD | -8,00%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Evaxion Biotech A/S

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden